P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining.

Stoetzer, Oliver J.; Munker, Reinhold; Darsow, M.; Wilmanns, W.

doi:10.3892/or.6.2.455

Cited by 8 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…“Positive” mesothelial markers also have been introduced as part of the panel, including OV632, thrombomodulin, CK 5/6, calretinin, HBME‐1, N‐cadherin, CD44S, and WT1, also with varying results 5, 18, 20, 24, 25, 29, 30, 35–37, 39, 40, 43, 45–49, 51–63. Finally, there is speculation that markers such as p53, E‐cadherin, and MOC‐31 may be useful for the identification of reactive mesothelial cells 43, 46, 47, 64…”

Section: Adenocarcinoma Versus Mesotheliomamentioning

confidence: 99%

See 1 more Smart Citation

Immunocytochemistry in effusion cytology

Fetsch

Abati

2001

Cancer

130

118

View full text Add to dashboard Cite

METHODS.The authors review the most commonly used cytologic preparations, fixatives, and antibodies used in effusion ICC. RESULTS.Through the utilization of cell block preparations and a panel of antibodies appropriate for the differential diagnosis in question, ICC conditions utilized in surgical pathology can be most closely replicated. CONCLUSIONS. ICC may provide reliable insights into various diagnostic dilemmasin effusion cytology, provided that laboratory standardization practices are fol- Some of the greatest diagnostic dilemmas in cytopathology are in the realm of effusion cytology. Hyperplastic mesothelial cells observed in various benign conditions can undergo cytologic alterations, mimicking malignant cells. [1][2][3][4] Extensive morphologic overlap also exists between malignant mesothelial cells and metastatic carcinoma cells. [1][2][3][4] In many cases, a definitive diagnosis cannot be reached based on morphology alone; thus, the diagnostic accuracy of effusion cytology is enhanced though the utilization of ancillary techniques.Electron microscopy has long been considered the "gold standard" for the diagnosis of malignant mesothelioma (MM) through the demonstration of numerous long, complex microvilli. Unfortunately, microvilli can vary in length and number from tumor-to-tumor as well as within a tumor, and the presence of short microvilli does not always exclude a diagnosis of MM. Currently, immunohistochemical stains that are widely utilized as diagnostic discriminators for the aforementioned diagnoses recognize both epithelial-derived and mesothelial cells. The seminal studies outlining the sensitivity and specificity of these antibodies were performed on formalin fixed, paraffin embedded surgical pathology specimens. However, large-scale cytology studies evaluating the same antibodies for use in effusion cytology have been performed on a myriad of preparations (i.e., ethanol-fixed smears and cytospins, ThinPrep [Cytyc Corporation, Boxbourough, MA] preparations, airdried cytospins, and formalin fixed cell blocks), thus accounting for less than reliable and reproducible results. In addition, a wide variety of opinions exist among pathologists with regard to the relative effectiveness of some markers used for this differentiation. In keeping with the contemporary viewpoint that the standardization of immunohistochemical methods is essential for reliable and reproducible results, we present what we have found to be the optimal approach for the utilization of immunohistochemistry in effusion cytology, a view that we believe approximates the current procedures utilized in surgical pathology samples most closely. 6 -9 In our experience, participation in the College of American Pathologists laboratory inspection and proficiency testing programs has contributed greatly to improving our immunocytochemistry (ICC) services, moving them toward a higher degree of standardization. -9 Specimen ProcessingTo achieve optimal specimen processing for ICC, effusion samples should be received in the cytology labor...

show abstract

Section: Adenocarcinoma Versus Mesotheliomamentioning

confidence: 99%

“…CEA first was described as a marker for colon carcinoma 4, 24, 31, 41, 44, 56, 64. It is highly specific for ACA cells, and typically is negative in benign, reactive, and MM cells 31, 75.…”

Section: Adenocarcinoma Versus Mesotheliomamentioning

confidence: 99%

Immunocytochemistry in effusion cytology

Fetsch

Abati

2001

Cancer

130

118

View full text Add to dashboard Cite

show abstract

“…They advised to use a panel of immunocytochemical stains to make this distinction in cytological effusions. Consistent with the role of p53 in controlling cellular proliferation, it was hypothesized that there was an association between p53 positivity and the number of ki67 positive cells in different neoplasms, suggesting that aberrant p53 expression is enhanced by cellular proliferation [23]. To verify whether the simultaneous association of p53 and ki67 immunodetection could help in differentiating malignant from benign effusions with a high reliability, the comparative expression of both markers was estimated and correlated with clinico-cytological diagnosis.…”

Section: Discussionmentioning

confidence: 96%

“…In the current study smears having >5% positive nuclei were considered positive [16,20]. Stoetzer et al [23] investigated four different monoclonal antibodies against p53 for the diagnosis of malignancy in effusions. They reported that the used antibodies reacted with 52-75% of malignant effusions but also with 38-80% of benign effusions.…”

Section: Discussionmentioning

confidence: 98%

Diagnostic value of p53 and ki67 immunostaining for distinguishing benign from malignant serous effusions

Hafez

Tahoun

2011

Journal of the Egyptian National Cancer Institute

View full text Add to dashboard Cite

Benign and malignant effusions showed significantly different staining pattern for p53 and ki67. When used individually, p53 immunostaining can truly diagnose 75.6% and 94% of the malignant and benign cases, respectively. ki67 immunostaining can correctly identify 73.2% and 66% of the malignant and benign cases, respectively. When used in combination, 91.7% of p53 and ki67 positive cases were malignant while 94% of p53 and ki67 negative cases were benign. Hence they could be used when the cytomorphology fails to provide a definitive diagnosis.

show abstract

“…Polysomy of chromosome 7 or 9 is a common finding in malignant mesothelioma but uncommon in reactive mesothelioma [52]. P53 mutations are the most frequent genetic changes in human cancer and translate into an over-expression of p53 protein detectable by immunhistochemistry [53]. Alterations of the p53 gene may lead to the production of detectable p53-antibodies [54].…”

Section: Tumor Growth Factors and Chromosomal Analysismentioning

confidence: 99%